BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test

About this update from Biomark Diagnostics, Inc.

BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in over 15,000 samples across Quebec, France, and Germany. Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, today announced a major operational milestone that underscores the strength of Canadian life sciences innovation. Coinciding with the global spotlight on Canadian medical innovation taking the stage at the BIO International Convention this week, the Company has officially received formal patent allowances from both the Canadian Intellectual Property Office (CIPO) and the European Patent Office (EPO) for its groundbreaking lung cancer early detection technology. The underlying approach represents a significant leap forward in precision oncology. BioMark's minimally invasive blood test leverages a newly patented algorithm designed to boost screening rates and catch non-small cell lung cancer (NSCLC) at its earliest, most treatable stages. While lung cancer remains a leading cause of mortality worldwide, traditional screening methods often fail to catch the disease before it advances. "The clinical validation of BioMark's metabolomics platform is anchored in exceptionally robust data, having already shown immense promise across more than 15,000 blood samples collected throughout Quebec, France, and Germany," said Rashid Ahmed Bux, CEO and Founder of BioMark Diagnostics. "The simultaneous allowances from both CIPO and the EPO represent a profound validation of our scientific approach and the clinical significance of our metabolomics platform. These are not peripheral claims; they protect the core metabolic signatures and advanced algorithms driving our screening panel. This vast multi-jurisdictional clinical asset underscores the reliability, reproducibility, and potential of the platform across diverse population groups." Looking ahead, BioMark continues to advance corresponding patent applications actively under prosecution in additional major markets, including the United States, China, and Japan, while preparing for the upcoming commercial launch later this year. The ...

View stock analysis, news, and events for Biomark Diagnostics, Inc.